Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study
Apatinib combined with irinotecan demonstrates modest efficacy with manageable safety profiles in HER2-negative patients with advanced gastric or GEJ adenocarcinoma for whom first-line treatment has failed. Further prospective studies are warranted.
Authors
- Shirong Cai (ORCID: https://orcid.org/0000-0001-8315-9989)
- Ran Wei (ORCID: https://orcid.org/0000-0003-4293-6686)
- Jiajia Huang (ORCID: https://orcid.org/0000-0002-9953-8729)
- Qian Chen (ORCID: https://orcid.org/0000-0001-6481-5776)
- Jin-ping Ma
- Ertao Zhai (ORCID: https://orcid.org/0000-0002-8459-2968)
- Jialin Li (ORCID: https://orcid.org/0000-0002-5879-8954)
- Jianjun Peng (ORCID: https://orcid.org/0000-0002-5869-8013)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Journal of Gastrointestinal Cancer
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1007/s12029-025-01259-z
- Citations
- 2
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.04